E Fund Management’s Vir Biotechnology VIR Stock Holding History

E Fund Management’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$151K	Buy	+16,896	New	+$135K	﹤0.01%	461
2025 Q2	$74.1K	Sell	14,698 -1,295	-8%	-$6.94K	﹤0.01%	381
2025 Q1	$104K	Buy	+15,993	New	+$142K	0.01%	380
2024 Q4	–	Sell	-11,170	Closed	-$83.7K	–	414
2024 Q3	$83.7K	Buy	+11,170	New	+$97K	﹤0.01%	344
2024 Q2	–	Sell	-20,761	Closed	-$210K	–	381
2024 Q1	$210K	Sell	20,761 -664	-3%	-$6.76K	0.01%	337
2023 Q4	$216K	Sell	21,425 -5,557	-21%	-$50.8K	0.01%	270
2023 Q3	$253K	Buy	26,982 +10,220	+61%	+$146K	0.02%	224
2023 Q2	$411K	Sell	16,762 -319	-2%	-$8.01K	0.03%	161
2023 Q1	$397K	Buy	17,081 +903	+6%	+$23.1K	0.03%	168
2022 Q4	$409K	Sell	16,178 -5,106	-24%	-$125K	0.03%	177
2022 Q3	$410K	Buy	21,284 +2,345	+12%	+$59.6K	0.04%	178
2022 Q2	$482K	Buy	18,939 +6,656	+54%	+$155K	0.04%	148
2022 Q1	$316K	Buy	+12,283	New	+$364K	0.01%	184

Other funds holding VIR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

GSK plc London $599M AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

E Fund Management's VIR Position: Q1 2026 in Review

E Fund Management opened a new position in Vir Biotechnology (VIR) in Q1 2026: 16,896 shares worth $151K. The stake represents ﹤0.01% of the portfolio and ranks #461 among its holdings. This is a return to the name: E Fund Management previously reported a position in VIR as recently as Q2 2025.

E Fund Management first reported a position in VIR in Q1 2022 and has held it in 13 quarters since. The position peaked at $482K in Q2 2022. 251 funds tracked by Wall St. Rank hold VIR as of Q1 2026.

E Fund Management held 16,896 shares of Vir Biotechnology worth $151K as of Q1 2026.
Vir Biotechnology was a new E Fund Management position in Q1 2026.
Vir Biotechnology made up ﹤0.01% of E Fund Management's portfolio in Q1 2026, its #461 holding.
E Fund Management first reported a position in Vir Biotechnology in Q1 2022 and has held it in 13 quarters since.
E Fund Management's Vir Biotechnology position peaked at $482K in Q2 2022.
251 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2026.

Based on E Fund Management's 13F filing for Q1 2026, filed 13 Apr 2026.